Coherus Oncology (CHRS) Capital Expenditures Growth (5y) (2018 - 2025)
Coherus Oncology (CHRS) Capital Expenditures Growth (5y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Coherus Oncology | 199.82 Mn | 32.78 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 54.48% |
| Jun 30, 2025 | -189.90% |
| Mar 31, 2025 | 21.49% |
| Jun 30, 2024 | -194.57% |
| Mar 31, 2024 | -254.85% |
| Dec 31, 2023 | 102.44% |
| Jun 30, 2023 | 82.06% |
| Mar 31, 2023 | 13.42% |
| Dec 31, 2022 | 15.09% |
| Sep 30, 2022 | -24.08% |
| Jun 30, 2022 | -1.75% |
| Mar 31, 2022 | -18.31% |
| Dec 31, 2021 | -41.10% |
| Jun 30, 2021 | 16.93% |
| Mar 31, 2021 | -41.67% |
| Sep 30, 2020 | 122.72% |
| Jun 30, 2020 | 30.69% |
| Mar 31, 2020 | 6.31% |
| Dec 31, 2019 | 20.74% |
| Sep 30, 2019 | -14.95% |